EUVIMEDEUVIMED entdecken
Querschnittstudie

Serum concentrations of valsartan and sacubitrilat, the active metabolite of sacubitril, in patients with heart failure with reduced ejection fraction: results of a pilot cross-sectional study

Marie Lazarova, Romana Urinovska, Ivana Kacirova iD, Milan Grundmann, Jozef Dodulik, Jan Vaclavik iD

Expert Review of Clinical Pharmacology · 2025

DOI: 10.1080/17512433.2025.2519644 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift Expert Review of Clinical Pharmacology, 2025. Verfasst von Marie Lazarova und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Cardiology, University Hospital Ostrava, Ostrava, Czech Republic. Hauptthemen laut MEDLINE: Valsartan, Aminobutyrates, Heart Failure, Tetrazoles. Die Arbeit nennt 54 Literaturangaben. Gefördert von: Ministry of Health, the Czech Republic, Conceptual Development of Research Organization, FNOs/2023.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Sacubitril/valsartan is used to treat heart failure. It consists of sacubitril (its active metabolite, sacubitrilat, acts as a neprilysin inhibitor) and valsartan (an angiotensin II type 1 receptor blocker). RESEARCH DESIGN AND METHODS: In this study, the minimum serum concentrations of valsartan and sacubitrilat were analyzed in patients with heart failure with reduced ejection fraction. RESULTS: Serum concentrations of valsartan ranged from 75 to 11,700 µg/L and of sacubitrilat from 607 to 17,646 µg/L. Wide interindividual variability was observed in the serum concentrations of valsartan and sacubitrilat after administration of the same dose. Patients with NYHA class III used a significantly lower dose per day and per kilogram of body weight than those with NYHA class I/II; however, the measured concentrations of valsartan and sacubitrilat did not differ between the two groups. For both drugs, an inverse correlation was found between the weight-adjusted apparent clearance and serum creatinine and urea concentrations, sacubitrilat levels, and estimated glomerular filtration rate. CONCLUSIONS: Valsartan and sacubitrilat concentrations showed wide inter-individual variability at the same dose, which could lead to both toxicity and suboptimal concentrations, with the risk of worsening clinical condition. Patients with reduced cardiac and renal functions are at a higher risk of overdose. [Figure: see text].

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ValsartanAminobutyratesHeart FailureTetrazolesAngiotensin II Type 1 Receptor BlockersAngiotensin Receptor AntagonistsHumansBiphenyl CompoundsMaleFemaleDrug CombinationsStroke VolumePilot ProjectsAgedMiddle AgedCross-Sectional StudiesNeprilysinDose-Response Relationship, DrugAged, 80 and over

Stichwörter der Autor:innen

Heart failureconcentrationsmonitoringsacubitrilvalsartan

Substanzen

ValsartanAminobutyratesBiphenyl CompoundsDrug Combinationssacubitril and valsartan sodium hydrate drug combinationTetrazolesAngiotensin II Type 1 Receptor BlockersAngiotensin Receptor AntagonistsNeprilysinsacubitril

Autor:innen und Institutionen

  • Department of Internal Medicine and Cardiology, University Hospital Ostrava, Ostrava, Czech Republic.
  • Department of Internal Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
  • Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, Ostrava, Czech Republic.
  • Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.

ORCID-Profile: Ivana Kacirova, Jan Vaclavik

Förderung

  • Ministry of Health, the Czech Republic, Conceptual Development of Research Organization, FNOs/2023

Zitieren

APA

Lazarova, M., Urinovska, R., Kacirova, I., Grundmann, M., Dodulik, J., & Vaclavik, J. (2025). Serum concentrations of valsartan and sacubitrilat, the active metabolite of sacubitril, in patients with heart failure with reduced ejection fraction: results of a pilot cross-sectional study. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2025.2519644

Vancouver

Lazarova M, Urinovska R, Kacirova I, Grundmann M, Dodulik J, Vaclavik J. Serum concentrations of valsartan and sacubitrilat, the active metabolite of sacubitril, in patients with heart failure with reduced ejection fraction: results of a pilot cross-sectional study. Expert Review of Clinical Pharmacology. 2025. doi:10.1080/17512433.2025.2519644

BibTeX
@article{Lazarova2025,
  author = {Lazarova, Marie and Urinovska, Romana and Kacirova, Ivana and Grundmann, Milan and Dodulik, Jozef and Vaclavik, Jan},
  title = {Serum concentrations of valsartan and sacubitrilat, the active metabolite of sacubitril, in patients with heart failure with reduced ejection fraction: results of a pilot cross-sectional study},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2025},
  doi = {10.1080/17512433.2025.2519644}
}
Kostenlos starten →